Table 2.
Qualitative and quantitative characteristics of included studies
| First author | Year of publication | STARD evaluation % (n/34) | PET CT (Yes/No) | PET scanner | Methionine dose (range or mean MBq/mCi) | Semi-quantitative analysis | Tumour ROI | Contralateral ROI region |
| Berntsson | 2013 | 47 (16/34) | Yes | ECAT EXACT HR +/Discovery ST | NA | Uptake ratio (NOS) | Max tumour | GM |
| Boss | 2010 | 53 (18/34) | Yes | Biograph 16 | 585–764 | Uptake ratio (NOS) | Mean tumour | Frontal GM |
| Coope | 2007 | 56 (19/34) | Yes | ECAT EXACT HR + | 740 | Uptake ratio (NOS) | Max tumour | Mirror region |
| Gumprecht | 2007 | 41 (14/34) | Yes | ECAT HR | 300–400 | Uptake ratio (NOS) | Mean tumour | GM |
| Kameyama | 1990 | 29 (10/34) | Yes | ECAT II/PT-931 | 222–925/6–25 | SUV | SUV tumour | SUV GM |
| Miyake | 2012 | 44 (15/34) | Yes | ECAT EXACT HR + | 113–389 | SUV | SUV max tumour | SUV mean in normal brain (NOS) |
| Ogawa | 1993 | 32 (11/34) | No (CT and PET) | Headtome III/Headtome IV | 555–1,480/15–40 | SUV | SUV tumour | SUV temporal GM |
| Okita | 2014 | 50 (17/34) | Yes | Eminence Sophia SET-3000 GCT/X | 111–222/3–6 | SUV | SUV max tumour | SUV mean frontal GM |
| Sadeghi | 2006 | 44 (15/34) | Yes | ECAT 962 h + | 260 | Uptake ratio (NOS) | Max tumour | Corona radiata |
| Tateishi | 2014 | 62 (21/34) | Yes | Biograph 16 | 370 | SUV | SUV max tumour | SUV GM |
| Tietze | 2015 | 44 (15/34) | Yes | Biograph PET/CT system | 500 | Uptake ratio (NOS) | Max tumour | GM |
| Torii | 2005 | 44 (15/34) | No (MRI and PET) | Headtome IV | 7.4/0.2 per kg | Uptake ratio (NOS) | Max tumour | Frontal GM |
| Yamamoto | 2008 | 56 (19/34) | Yes | ECAT EXACT HR + | 6 per kg | SUV | SUV tumour | SUV mean GM |
GM, grey matter; NA, not available; NOS, not otherwise specified; PET, positron emission tomography; ROI, region of interest; STARD, standards for reporting studies of diagnostic accuracy (% adherence to 34 quality items); SUV, standardized uptake value.